# Project 2

> **NIH NIH P01** · WAYNE STATE UNIVERSITY · 2024 · $208,829

## Abstract

Project Summary
Survival for breast, prostate and colorectal cancer has improved dramatically over the past three
decades as a result of advances in treatment and screening for the detection of these common
cancers at an earlier stage. However, African Americans (AAs) still suffer from a higher mortality
rate after diagnosis of these cancers compared with other racial and ethnic groups. One of the
consequences of prolonged survival is the possibility of developing one or more new primary
cancers in their lifetime. It has been estimated that overall nearly 10% of cancer survivors will be
diagnosed with a second primary cancer, with some variability in estimates across studies which
is not thoroughly understood, particularly among AAs, who we’ve been shown to have poorer
survival after a second primary diagnosis. Understanding the underlying causes of second
primary cancers is critical in order to design strategies for risk mitigation and early detection.
Importantly, the multiple primary cancer (MPC) phenotype can be a used to understand both
genetic susceptibility and environmental risk determinants.
The proposed investigation will build upon the Detroit Research on Cancer Survivors (ROCS)
study, one of the largest cohorts conducted exclusively among AA cancer survivors to understand
the multiplex causes of poorer outcomes in the population. We will focus both on breast, prostate
and colorectal cancer survivors enrolled in Detroit ROCS who developed a second primary cancer
and use the existing infrastructure to enroll new participants diagnosed with MPCs. We will 1).
sequence DNA collected from whole blood or saliva of 1000 participants diagnosed with MPCs
(500 AA and 500 non-Hispanic white (NHW)) as well as 500 AA survivors diagnosed with a single
primary cancer (SPC) to characterize the mutational landscape overall and compare the spectrum
and prevalence of pathogenic and likely pathogenic mutations by race and MPC/SPC status. We
will 2). calculate cancer site-specific polygenic risk scores (PRS) using largely existing genotype
data to understand the contribution of more common variants and PRS to the risk of MPCs.
Finally, we will 3). evaluate select environmental risk factors collected as part of the Detroit ROCS
survey for their association with MPC using a 3:1 matched design comparing these participants
to those diagnosed with first and only primary breast, prostate and colorectal cancer (1500 SPCs).
This study is the first of its kind to address the contributing factors in the development of MPCs
among AA cancer survivors.

## Key facts

- **NIH application ID:** 10767510
- **Project number:** 1P01CA272239-01A1
- **Recipient organization:** WAYNE STATE UNIVERSITY
- **Principal Investigator:** Jennifer L Beebe-Dimmer
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $208,829
- **Award type:** 1
- **Project period:** 2024-02-13 → 2029-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10767510

## Citation

> US National Institutes of Health, RePORTER application 10767510, Project 2 (1P01CA272239-01A1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10767510. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*